


# Hepatitis C rarely treated in high-risk postpartum Medicaid beneficiaries

May 17 2022



HCV viral response to ledipasvir–sofosbuvir during pregnancy. Data stated below the chart are median (range). PK-1 visit was between 10 and 21 days after treatment initiation. PK-2 visit was between 32 and 47 days after treatment initiation. PK-3 visit was between 59 and 74 days after treatment initiation. HCV=hepatitis C virus. PK-1=first pharmacokinetic visit. PK-2=second pharmacokinetic visit. PK-3=third pharmacokinetic visit. SVR12=sustained virological response 12 weeks after completion of treatment. Credit: *The Lancet Microbe* (2020). DOI: 10.1016/S2666-5247(20)30062-8

Nearly a third of pregnant Medicaid beneficiaries who have opioid use disorder and are screened for hepatitis C test positive for the potentially deadly, liver-destroying virus, according to new findings made by a research consortium led by University of Pittsburgh School of Public Health scientists.

And—despite the availability of a pill that cures the disease—fewer than a fifth of those patients received follow-up care for their hepatitis C diagnosis within six months of giving birth, the scientists report today in the May issue of the journal *Obstetrics & Gynecology*.

"When we first saw these results, we thought, 'This is far too low of a treatment rate and there must be an error in our analysis,'" said lead author Marian Jarlenski, Ph.D., M.P.H., associate professor of health policy and management at Pitt Public Health. "But then I thought about my own experiences with referrals to medical specialists and it made sense. Navigating the medical system to get an appointment with an infectious diseases specialist, particularly after giving birth and while managing a chronic disorder, such as substance use, can be incredibly difficult."

Hepatitis C is passed from mother to baby in about 6% of pregnancies and the U.S. Centers for Disease Control and Prevention (CDC) has long recommended that people with [substance use disorders](#) be screened for hepatitis C while pregnant. With the development of highly effective oral medications that can cure hepatitis C, in 2020 the [CDC expanded its screening recommendation](#) to include all pregnant patients.

As the largest payor of medical and health-related services, Medicaid covers more than 4 in 10 births in the U.S. The Affordable Care Act expanded Medicaid by incentivizing states to allow access to people with

incomes slightly above the federal poverty level.

The Medicaid Outcomes Distributed Research Network, led by study co-author Julie Donohue, Ph.D., professor and chair of health policy and management at Pitt Public Health, obtained de-identified, standardized data from the six states included in this study: Pennsylvania, West Virginia, Kentucky, Delaware, North Carolina and Maine. Data from 23,780 Medicaid recipients with an [opioid use disorder](#) diagnosis and a live or stillbirth between 2016 and 2019 were analyzed.

About 70% of the people included in the study were tested for hepatitis C, and 31% of those were diagnosed with the virus. At three-months postpartum, 3.2% of those had received any follow-up visit or medication to treat the virus, and at six months that rate had only risen to 5.9%.

The American Rescue Plan Act—signed into law in 2021—created a pathway that goes into effect this month to allow states to extend Medicaid coverage for pregnant people up to an entire year postpartum, theoretically allowing someone who discovered they had hepatitis C while pregnant to get treated after delivery.

"But what we're finding is that it's not that easy—as our research shows, telling a new parent they have hepatitis C and need to make an appointment with an infectious diseases specialist simply isn't translating into treatment," Jarlenski said. "Now more than ever, with universal hepatitis C screening during pregnancy, the existence of a pill that cures this devastating illness and expanded postpartum Medicaid coverage to pay for that treatment, finding a sustainable pathway to care is critical."

Jarlenski said a potential way to better ensure patients positive for hepatitis C receive treatment is to get them that treatment while they're still pregnant and highly engaged in care. A small phase 1 clinical trial

led by coauthor Catherine Chappell, M.D., M.Sc., assistant professor of obstetrics, gynecology and reproductive sciences in Pitt's School of Medicine, and published in *The Lancet Microbe* showed that all nine participants who were positive for hepatitis C and took the medication while in their second trimester of pregnancy were cured and gave birth to healthy, [hepatitis](#)-free babies. Larger trials are ongoing, and Jarlenski said she's hopeful treatment during pregnancy can help narrow the care gap.

**More information:** Marian Jarlenski et al, Postpartum Follow-up Care for Pregnant Persons With Opioid Use Disorder and Hepatitis C Virus Infection, *Obstetrics & Gynecology* (2022). [DOI: 10.1097/AOG.0000000000004760](#)

Catherine A Chappell et al, Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study, *The Lancet Microbe* (2020). [DOI: 10.1016/S2666-5247\(20\)30062-8](#)

Provided by University of Pittsburgh Schools of the Health Sciences

Citation: Hepatitis C rarely treated in high-risk postpartum Medicaid beneficiaries (2022, May 17) retrieved 27 April 2024 from <https://medicalxpress.com/news/2022-05-hepatitis-rarely-high-risk-postpartum-medicaid.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--